Table 3. All grades AEs suspected to be study drug related occurring in at least 5% of all patients (safety cohort).

	Weekly schedule							Twice-weekly schedule
	2.5 mg (N=3)	5 mg (N=5)	10 mg (N=7)	20 mg (N=6)	30 mg (N=5)	50 mg (N=22)	60 mg (N=5)	25 mg (N=11)	All pts (N=64)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Pts with ≥1 drug-related AEs	1 (33)	3 (60)	4 (57)	6 (100)	5 (100)	22 (100)	5 (100)	11 (100)	57 (89)
Constitutional
Asthenia	0	2 (40)	2 (29)	2 (33)	2 (40)	11 (50)	3 (60)	4 (36)	26 (41)
Insomnia	0	0	0	0	1 (20)	9 (41)	2 (40)	4 (36)	16 (25)
Gastrointestinal
Diarrhoea	0	3 (60)	2 (29)	6 (100)	4 (80)	18 (82)	5 (100)	9 (82)	47 (73)
Nausea	0	0	0	3 (50)	1 (20)	6 (27)	2 (40)	2 (18)	14 (22)
Anorexia	1 (33)	0	2 (29)	1 (17)	1 (20)	7 (32)	2 (40)	2 (18)	16 (25)
Abdominal pain	0	0	0	4 (67)	1 (20)	3 (14)	1 (20)	1 (9)	10 (16)
Vomiting	0	1 (20)	0	1 (17)	0	5 (23)	2 (40)	0	9 (14)
Weight loss	0	0	1 (14)	0	0	2 (9)	1 (20)	0	4 (6)
Neurology
Dizziness	0	2 (40)	0	1 (17)	0	6 (27)	1 (20)	2 (18)	12 (19)
Tremor	0	0	0	0	0	6 (27)	3 (60)	3 (27)	12 (19)
Ataxia	0	0	0	0	0	3 (14)	0	3 (27)	6 (10)
Cerebellar syndrome	0	0	0	0	0	1 (4)	2 (40)	2 (18)	5 (8)
Balance disorder	0	0	0	0	0	3 (14)	1 (20)	0	4 (6)
Headache	0	0	0	1 (17)	0	2 (9)	0	1 (9)	4 (6)
Muscle spasms	0	0	0	0	1 (20)	2 (9)	1 (20)	0	4 (6)
Laboratory
ALT increase	0	0	0	1 (17)	0	2 (9)	1 (20)	1 (9)	5 (8)
AST increase	0	0	0	1 (17)	0	2 (9)	1 (20)	1 (9)	5 (8)

Abbreviations: AE=adverse events; ALT=alanine transaminase; AST=aspartate aminotransferase; pts=patients.